Neuronetics Gets Expanded Clearance For TMS Therapy System

The US FDA has cleared the NeuroStar transcranial magnetic stimulation system to treat depression in adolescents 15 through 21, making it the first and only such treatment the agency has cleared for this age group.

Depression
• Source: Shutterstock

The Food and Drug Administration has cleared the NeuroStar transcranial magnetic stimulation system (TMS) from Neuronetics as an adjunct treatment of major depressive order in adolescents, the company recently announced.

In July 2022, the FDA cleared the system to treat anxious depression, expanding the clearance at that time from its previous clearance to treat obsessive-compulsive disorder

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

More from Policy & Regulation